O	0	1	[
O	1	7	Effect
O	8	10	of
B-intervention	11	17	shugan
I-intervention	18	26	liangxue
O	27	35	compound
O	36	39	for
O	40	49	relieving
B-condition	50	53	hot
I-condition	54	61	flashes
O	62	64	in
O	65	71	breast
O	72	78	cancer
O	79	87	patients
O	87	88	]
O	88	89	.

O	90	92	To
O	93	100	observe
O	101	104	the
O	105	111	effect
O	112	114	of
O	115	121	Shugan
O	122	130	Liangxue
O	131	139	Compound
O	140	141	(
O	141	144	SLC
O	144	145	)
O	146	149	for
O	150	159	relieving
O	160	163	hot
O	164	171	flashes
O	172	174	in
O	175	181	breast
O	182	188	cancer
O	189	197	patients
O	198	207	medicated
O	208	212	with
O	213	222	tamoxifen
O	222	223	.

O	224	225	A
O	226	236	randomized
O	236	237	,
O	238	244	double
O	245	250	blind
O	251	259	clinical
O	260	265	trial
O	266	269	for
O	270	279	observing
O	280	283	the
O	284	295	therapeutic
O	296	303	effects
O	304	306	of
O	307	310	SLC
O	311	314	was
O	315	322	carried
O	323	326	out
O	327	329	on
B-total-participants	330	332	73
B-eligibility	333	339	breast
I-eligibility	340	346	cancer
I-eligibility	347	355	patients
O	356	368	hospitalized
O	369	373	from
O	374	381	October
O	382	386	2004
O	387	389	to
O	390	398	November
O	399	403	2006
O	403	404	,
B-eligibility	405	408	who
I-eligibility	409	413	were
I-eligibility	414	421	treated
I-eligibility	422	426	with
I-eligibility	427	436	tamoxifen
I-eligibility	436	437	,
I-eligibility	438	441	and
I-eligibility	442	450	revealed
I-eligibility	451	454	hot
I-eligibility	455	462	flashes
O	462	463	.

O	464	468	They
O	469	473	were
O	474	482	randomly
O	483	491	assigned
O	492	494	to
O	495	498	two
O	499	505	groups
O	505	506	,
O	507	510	the
B-intervention-participants	511	513	37
O	514	516	in
O	517	520	the
O	521	528	treated
O	529	534	group
O	535	542	treated
O	543	545	by
O	546	549	SLC
O	549	550	,
O	551	554	and
O	555	558	the
B-control-participants	559	561	36
O	562	564	in
O	565	568	the
O	569	576	control
O	577	582	group
O	583	590	treated
O	591	595	with
B-control	596	603	placebo
O	603	604	.

O	605	611	Taking
O	612	615	the
O	616	627	improvement
O	628	630	of
O	631	634	hot
O	635	642	flashes
O	643	645	as
O	646	648	an
O	649	652	end
O	653	658	point
O	659	664	index
O	665	668	and
O	669	673	that
O	674	676	of
O	677	682	sleep
O	683	685	as
O	686	687	a
O	688	697	secondary
O	698	703	index
O	703	704	,
O	705	708	the
O	709	716	effects
O	717	719	of
O	720	729	treatment
O	730	734	were
O	735	743	compared
O	744	746	by
O	747	756	Kupperman
O	757	764	scoring
O	765	769	with
O	770	773	the
O	774	781	average
O	782	787	times
O	788	790	of
O	791	794	hot
O	795	802	flashes
O	803	806	per
O	807	810	day
O	811	814	and
O	815	824	condition
O	825	827	of
O	828	833	sleep
O	834	840	within
O	841	842	1
O	843	847	week
O	848	854	before
O	855	864	treatment
O	865	867	as
O	868	876	baseline
O	876	877	.

O	878	881	The
O	882	889	effects
O	890	892	on
B-total-participants	893	895	66
O	896	904	patients
O	905	906	(
B-intervention-participants	906	908	33
O	909	911	in
O	912	915	the
O	916	923	treated
O	924	929	group
O	930	933	and
B-control-participants	934	936	33
O	937	939	in
O	940	943	the
O	944	951	control
O	952	957	group
O	957	958	)
O	959	963	were
O	964	973	evaluable
O	973	974	.

O	975	977	In
O	978	981	the
O	982	989	treated
O	990	995	group
B-outcome	996	999	hot
I-outcome	1000	1007	flashes
I-outcome	1008	1019	disappeared
O	1020	1022	in
B-iv-bin-abs	1023	1024	5
O	1025	1033	patients
O	1034	1035	(
B-iv-bin-abs	1035	1037	15
I-iv-bin-abs	1037	1038	.
I-iv-bin-abs	1038	1039	2
I-iv-bin-abs	1039	1040	%
O	1040	1041	)
O	1041	1042	,
B-outcome	1043	1051	relieved
O	1052	1054	in
B-iv-bin-abs	1055	1057	14
O	1058	1059	(
B-iv-bin-percent	1059	1061	42
I-iv-bin-percent	1061	1062	.
I-iv-bin-percent	1062	1063	4
I-iv-bin-percent	1063	1064	%
O	1064	1065	)
O	1066	1069	and
B-outcome	1070	1079	unchanged
O	1080	1082	in
B-iv-bin-abs	1083	1085	14
O	1086	1087	(
B-iv-bin-percent	1087	1089	42
I-iv-bin-percent	1089	1090	.
I-iv-bin-percent	1090	1091	4
I-iv-bin-percent	1091	1092	%
O	1092	1093	)
O	1093	1094	;
O	1095	1100	while
O	1101	1103	in
O	1104	1107	the
O	1108	1115	control
O	1116	1121	group
O	1121	1122	,
O	1123	1125	it
B-outcome	1126	1137	disappeared
O	1138	1140	in
B-cv-bin-abs	1141	1145	none
O	1145	1146	,
B-outcome	1147	1155	relieved
O	1156	1158	in
B-cv-bin-abs	1159	1161	10
O	1162	1163	(
B-cv-bin-percent	1163	1165	30
I-cv-bin-percent	1165	1166	.
I-cv-bin-percent	1166	1167	3
I-cv-bin-percent	1167	1168	%
O	1168	1169	)
O	1170	1173	and
B-outcome	1174	1183	unchanged
O	1184	1186	in
B-cv-bin-abs	1187	1189	23
O	1190	1191	(
B-cv-bin-percent	1191	1193	69
I-cv-bin-percent	1193	1194	.
I-cv-bin-percent	1194	1195	7
I-cv-bin-percent	1195	1196	%
O	1196	1197	)
O	1197	1198	,
O	1199	1209	comparison
O	1210	1217	between
O	1218	1224	groups
O	1225	1231	showed
O	1232	1243	significant
O	1244	1254	difference
O	1255	1256	(
O	1256	1257	P
O	1258	1259	=
O	1260	1261	0
O	1261	1262	.
O	1262	1265	012
O	1265	1266	)
O	1266	1267	.

O	1268	1270	As
O	1271	1274	for
O	1275	1278	the
B-outcome	1279	1288	condition
I-outcome	1289	1291	of
I-outcome	1292	1297	sleep
O	1297	1298	,
O	1299	1301	it
O	1302	1305	was
B-outcome	1306	1314	improved
O	1315	1317	in
B-iv-bin-abs	1318	1320	21
O	1321	1322	(
B-iv-bin-percent	1322	1324	63
I-iv-bin-percent	1324	1325	.
I-iv-bin-percent	1325	1326	6
I-iv-bin-percent	1326	1327	%
O	1327	1328	)
O	1329	1332	and
B-outcome	1333	1342	unchanged
O	1343	1345	in
B-iv-bin-abs	1346	1348	12
O	1349	1350	(
B-iv-bin-percent	1350	1352	36
I-iv-bin-percent	1352	1353	.
I-iv-bin-percent	1353	1354	4
I-iv-bin-percent	1354	1355	%
O	1355	1356	)
O	1357	1359	in
O	1360	1363	the
O	1364	1371	treated
O	1372	1377	group
O	1377	1378	;
O	1379	1384	while
O	1385	1388	the
B-outcome	1389	1398	condition
I-outcome	1399	1401	of
I-outcome	1402	1407	sleep
O	1408	1410	in
O	1411	1414	the
O	1415	1422	control
O	1423	1428	group
O	1429	1432	was
B-outcome	1433	1441	improved
O	1442	1444	in
B-cv-bin-abs	1445	1447	13
O	1448	1449	(
B-cv-bin-percent	1449	1451	39
I-cv-bin-percent	1451	1452	.
I-cv-bin-percent	1452	1453	4
I-cv-bin-percent	1453	1454	%
O	1454	1455	)
O	1456	1459	and
B-outcome	1460	1469	unchanged
O	1470	1472	in
B-cv-bin-abs	1473	1475	20
O	1476	1477	(
B-cv-bin-percent	1477	1479	60
I-cv-bin-percent	1479	1480	.
I-cv-bin-percent	1480	1481	6
I-cv-bin-percent	1481	1482	%
O	1482	1483	)
O	1483	1484	,
O	1485	1489	also
O	1490	1494	with
O	1495	1506	significant
O	1507	1517	difference
O	1518	1525	between
O	1526	1529	the
O	1530	1533	two
O	1534	1540	groups
O	1541	1542	(
O	1542	1543	P
O	1544	1545	=
O	1546	1547	0
O	1547	1548	.
O	1548	1551	002
O	1551	1552	)
O	1552	1553	.

O	1554	1557	SLC
O	1558	1560	is
O	1561	1570	effective
O	1571	1573	in
O	1574	1585	alleviating
O	1586	1595	tamoxifen
O	1595	1596	-
O	1596	1603	induced
O	1604	1607	hot
O	1608	1615	flashes
O	1616	1619	and
O	1620	1629	improving
O	1630	1633	the
O	1634	1643	condition
O	1644	1646	of
O	1647	1652	sleep
O	1652	1653	.
